abstract |
The specification describes the use of known tricyclic benzazepine vasopressin antagonists (see US 5,055,448 & US 4,766,108) and those tricyclic benzazepine vasopressin antagonists indicated by formula (I) to treat diseases characterised by excess renal reabsorption of water, congestive heart failure, liver cirrhosis, nephrotic syndrome, CNS injuries, lung disease and hyponatremia. |